Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 9, 2009 - Issue 9
Submit an article Journal homepage
52
Views
5
CrossRef citations to date
0
Altmetric
Meeting Report

Personalizing therapy for metastatic breast cancer

Patrick G Morris Fellow, Breast Cancer Medicine Service, Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. [email protected]
&
Clifford A Hudis Attending Physician and Chief, Breast Cancer Medicine Service, Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, [email protected]
Pages 1223-1226 | Published online: 10 Jan 2014

References

  • Hudis CA. Trastuzumab – mechanism of action and use in clinical practice. N. Engl. J. Med.357, 39–51 (2007).
  • Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med.355, 2733–2743 (2006).
  • Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344, 783–792 (2001).
  • Beeram M, Burris HA, Modi S et al. A Phase I study of trastuzumab–DM1 (T–DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC) Proc. Am. Soc. Clin. Oncol. (2008) (Abstract 1028).
  • Holden S, Beeram M, Krop I et al. A Phase I study of weekly dosing of trastuzumab–DM1 (T–DM1) in patients (pts) with advanced HER2+ breast cancer (BC). Proc. Am. Soc. Clin. Oncol. (2008) (Abstract 1029).
  • Vogel CL, Burris HA, Limentani S et al. A Phase II study of trastuzumab–DM1 (T–DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): final results. Proc. Am. Soc. Clin. Oncol. (2009) (Abstract 1017).
  • Gelmon KA, Fumoleau P, Verma S et al. Results of a Phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. Proc. Am. Soc. Clin. Oncol. (2008) (Abstract 1026).
  • Cortés J, Baselga J, Petrella T et al. Pertuzumab monotherapy following trastuzumab-based treatment: activity and tolerability in patients with advanced HER2 positive breast cancer. Proc. Am. Soc. Clin. Oncol. (2009) (Abstract 1022).
  • Modi S, Stopeck AT, Gordon MS et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a Phase I dose-escalation study. J. Clin. Oncol.25, 5410–5417, (2007).
  • Swaby R, Blackwell K, Jiang Z et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a Phase I/II study. Proc. Am. Soc. Clin. Oncol (2009) (Abstract 1004).
  • Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med.357, 2666–2676 (2007).
  • Miles D, Chan A, Romieu G. Randomized, double-blind, placebo-controlled, Phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Proc. Am. Soc. Clin. Oncol.26, (2008) (Late breaking abstract 1011).
  • Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol (2009) (Abstract 1005).
  • Miller KD, Chap LI, Holmes FA et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol.23, 792–799 (2005).
  • Conlin AK, Hudis CA, Bach A et al. Randomized Phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. (2009) (Abstract 1006).
  • Tutt A, Robson M, Garber JE et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. Proc. Am. Soc. Clin. Oncol. (2009) (Abstract CRA501).
  • O’Shaughnessy J, Osborne C, Pippen J et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized Phase II trial. Proc. Am. Soc. Clin. Oncol. (2009) (Abstract 3).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.